Baxter International Inc. is a global healthcare company with a market cap of $9.5 billion, specializing in medical products and therapies like renal care and medication delivery. However, BAX stock has dropped significantly over the past year compared to the broader market and the Health Care Select Sector. Despite reporting better-than-expected Q3 2025 adjusted EPS, Baxter’s shares plunged 14.5% due to missed revenue forecasts. Analysts expect BAX’s adjusted EPS to grow by 24.9% for the current fiscal year, but the consensus rating is a “Hold.” Goldman Sachs recently lowered Baxter’s price target to $22, with a mean price target of $26.77.

Read more at Barchart: Is Wall Street Bullish or Bearish on Baxter International Stock?